Zila Pharmaceuticals’ “Next Generation” ViziLite Plus with TBlue630 Features New Pearlescent™…
ViziLite® Plus with TBlue630, the emerging standard of care for the early detection of oral abnormalities that could lead to cancer, now includes Pearlescent™ retractors, replacing the earlier transparent devices. With an…